Eisai Co., Ltd. (ESALY) Research

Headquartered in Tokyo, Japan, Eisai Co., Ltd. is a pharmaceutical company that develops and markets a diverse range of medicinal products within Japan. Its extensive product lineup includes treatments for neurological conditions, such as Aricept for Alzheimer's disease and Lewy body dementia, Methycobal for peripheral neuropathy, and Fycompa, an antiepileptic drug for specific partial-onset and generalized tonic-clonic seizures. Eisai also offers Dayvigo, an anti-insomnia agent for adults. In the field of oncology, the company provides Lenvima, a molecularly targeted anticancer agent for thyroid cancer, renal cell carcinoma (in combination with everolimus), and hepatocellular carcinoma, alongside Halaven, a microtubule dynamics inhibitor used for breast cancer and liposarcoma. Other key pharmaceuticals include Lyrica for pain management, and Pariet, a proton-pump inhibitor effective against gastric and duodenal ulcers, reflux esophagitis, and Helicobacter pylori infections. The portfolio also features Humira, a fully human anti-TNF-alpha monoclonal antibody for autoimmune diseases like rheumatoid arthritis. Beyond prescription drugs, Eisai markets consumer health items such as Chocola BB Plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various third-class over-the-counter drugs, designated quasi-drugs, and food products with nutrient function. Originally founded in 1941 as Nihon Eisai Co., Ltd., the company adopted its current name, Eisai Co., Ltd., in 1955.

Open Eisai Co., Ltd. (ESALY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.